Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.

Rieke E AltenBogdan BatkoTomas HalaHideto KamedaSebastiao C RadominskiVira TseluykoGoran BabicCarol CronenbergerSarah HackleyMuhammad RehmanOliver von RichterMin ZhangStanley Cohen

Published in: RMD open (2019)

NCT02222493.

Keyphrases

placebo controlled
phase iii
double blind
open label
clinical trial
phase ii
study protocol
ulcerative colitis
randomized controlled trial